Fate Therapeutics

FATE THERAPEUTICS INC

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

movers image

$BTC

ACHR

AMBA

ARWR

BTBT

FATE

IREN

MNSO

MRNO

URBN

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday

Charles Schwab shutter

News

Intraday Update

Markets

Movers

Trading Ideas

AEON

AMIX

ANGO

ARVN

ATGL

CGBS

CHGG

CMND

EGHT

EOSE

FNKO

GRNQ

GROM

KOSS

LCFY

MTCH

NAAS

NEGG

NTWK

PACB

RDDT

SANA

SCHW

SFBS

SHOP

SHPW

SILO

SPRC

TKLF

VRPX

ZENV

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Konskie,,Poland,-,January,05,,2019:,Unitedhealth,Group,Logo,Displayed

JANX

NVAX

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America  And Other Big Stocks Moving Higher On Tuesday

Fate Therapeutics Inc

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

Press Releases

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Health Care

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Earnings

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Management

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

ADIA

CRSP

MESO

NBIX

PLUR

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Agenus

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

BeyondSpring

Compugen

Cellectis S.A. - American Depositary Shares

Cellectis

Caribou Biosciences

Elicio Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

RAPT Therapeutics

AVITA Medical

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Vaxart

Barclays

Baird

Stifel

Wedbush

Wells Fargo

Comments

Fate Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell